5263 studies found for:    vaccines
Show Display Options
Rank Status Study
1 Completed
Has Results
The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines
Condition: Hepatitis b
Interventions: Biological: 60mcg/1.0ml recombinant hepatitis B vaccine;   Biological: 30mcg/1.0ml recombinant hepatitis B vaccine;   Biological: 10mcg/1.0ml recombinant hepatitis B vaccine
2 Completed Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines
Condition: Prophylaxis of Avian Influenza Vaccine
Intervention: Biological: Fluad H5N1 Pandemic Influenza Vaccine
3 Active, not recruiting Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
Condition: Influenza
Interventions: Biological: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),;   Biological: Fluzone® Intradermal Influenza Virus Vaccine (2013-2014 formulation),;   Biological: Fluzone® High Dose Influenza Virus Vaccine (2013-2014 formulation)
4 Completed
Has Results
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
Conditions: Hepatitis B;   Acellular Pertussis;   Tetanus;   Poliomyelitis;   Diphtheria
Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: Prevenar;   Biological: Infanrix hexa;   Biological: Infanrix IPV Hib;   Biological: Infanrix penta;   Biological: Infanrix IPV;   Biological: Meningitec;   Biological: NeisVac-C;   Biological: Menitorix
5 Completed Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to 72 Months) Versus Control Vaccines
Condition: Influenza Disease
Interventions: Biological: Adjuvanted trivalent inactivated subunit influenza vaccine;   Biological: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine;   Biological: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
6 Completed Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever;   Yellow Fever
Interventions: Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus;   Biological: Yellow fever vaccine;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal Conjugated Vaccine;   Biological: Hepatitis A Pediatric Vaccine;   Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine;   Biological: Yellow Fever Vaccine;   Biological: Placebo (NaCl)
7 Unknown  Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Conditions: Pneumococcal Vaccines;   HIV;   HIV Infections
Intervention: Biological: Prevenar and Pneumo23
8 Completed
Has Results
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
Conditions: Encephalitis;   Japanese Encephalitis
Interventions: Biological: Japanese encephalitis chimeric virus vaccine (JE-CV);   Biological: Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)
9 Completed
Has Results
Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age
Condition: Influenza Disease
Interventions: Biological: Trivalent split influenza vaccine (TIV);   Biological: MF59-adjuvanted trivalent influenza vaccine (aTIV);   Biological: Licensed comparator trivalent split influenza vaccine (comparator TIV)
10 Completed Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study
Condition: FLU
Intervention: Biological: Influenza Trivalent Inactivated Vaccines
11 Completed
Has Results
Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old
Condition: Influenza
Interventions: Biological: Lot A of Influenza virus vaccine;   Biological: Lot B of Influenza virus vaccine;   Biological: Lot C of Influenza virus vaccine;   Biological: Comparator influenza virus vaccine;   Biological: All 3 consecutive lots of influenza virus vaccine pooled
12 Completed Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
Condition: Plague Vaccine
Interventions: Biological: rF1V vaccine (with Adjuvant);   Biological: rF1V vaccine (without Adjuvant)
13 Recruiting Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine;   Biological: CYD Dengue and Japanese Encephalitis Vaccines;   Biological: Japanese Encephalitis and CYD Dengue Vaccines
14 Completed
Has Results
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
Condition: Influenza
Interventions: Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV);   Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV);   Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV);   Biological: Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)
15 Completed
Has Results
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-IPV/Hib;   Biological: HBV;   Biological: PCV;   Biological: MMR
16 Completed
Has Results
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
Condition: Meningococcal Meningitis
Interventions: Biological: MenACWY-CRM conjugate vaccine;   Biological: Licensed comparator
17 Completed
Has Results
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
Condition: Influenza
Interventions: Biological: Cell culture-derived influenza subunit vaccine (cTIV);   Biological: Egg derived influenza subunit vaccine (eTIV_f)
18 Completed
Has Results
Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: Meningococcal ACWY conjugate vaccine (MenACWY-CRM);   Biological: Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap);   Biological: saline placebo
19 Completed
Has Results
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
Condition: Meningococcal Disease
Interventions: Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine.;   Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)
20 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + OMV vaccine (rMenB +OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years